Christopher Bowlus, M.D.

Christopher L. Bowlus, M.D.

Specialties

Gastroenterology and Hepatology

Internal Medicine

Department

Internal Medicine

Title

  • Acting Division Chief of Gastroenterology and Hepatology
  • Professor
To see if Christopher L. Bowlus is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Medical Group - Sacramento (J Street)

2825 J St., Suite 400
Sacramento, CA 95816
Driving Directions

Primary Phone:
916-734-2737

Additional Phone Numbers

Clinic Fax: 916-734-0804
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Technology has led to tremendous improvements in the care of patients, but the physician's greatest tool remains the ability to listen.

Clinical Interests

Christopher L. Bowlus specializes in autoimmune liver diseases, specifically primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. He also cares for patients with hepatitis B.

Research/Academic Interests

Dr. Bowlus is interested in elucidating the underlying genetic and immunologic causes of autoimmune liver diseases and using this information to develop more effective treatments for these conditions.

Division

Gastroenterology and Hepatology
UC Davis Medical Group, Sacramento - J Street

Center/Program Affiliation

UC Davis Medical Group

Education

M.D., St. Louis University School of Medicine, St. Louis, Missouri, 1990

B.A., UC San Diego, San Diego CA 1985

Residency

Internal Medicine, UC Davis Medical Center, Sacramento CA 1991-1993

Fellowships

Gastroenterology and Hepatology, Yale University School of Medicine, New Haven CT 1993-1996

Board Certifications

American Board of Internal Medicine, 2003

American Board of Internal Medicine, Gastroenterology and Hepatology, 2009

Professional Memberships

American Association for the Study of Liver Diseases

American College of Physicians

American Gastroenterology Association

Honors and Awards

American Liver Foundation, Postdoctoral Fellowship Award, 1994

Select Recent Publications

Bowlus CL. Primary sclerosing cholangitis: One disease or several? Clinical Liver Disease, 2014;3(2): 34-37.

Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL. New therapies for primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015 Jun;48(2-3):263-72.

Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL, Ansari AA, Yang GX, Wang J, Kenny TP, He XS, Mackay IR, Gershwin ME. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology, 2014;60(5): 1708-16.

Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL. Therapies for Primary Biliary Cirrhosis. Clin Rev Allergy Immunol. 2014.

Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev., 2014;13(4-5): 445-450.

Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis.Autoimmun Rev, 2014;13(4-5): 441-444.

Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, Bowlus CL, Yang GX, Leung PS, Ansari AA, Wu L, Coppel R, Gershwin ME. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. Hepatology, 2014;59(5):1944-53.

Tanaka H, Yang G, Iwakashi N, Knechtle S, Kawata K, Tsuneyama K, Leung P, Coppel R, Ansari A, Joh T, Bowlus C, Gershwin ME. Anti- CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013;174(3): 364-71.

Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, Næss S, Thomsen I, Mayr G, König IR, Hveem K, Cleynen I, Gutierrez- Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouillères O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M; UK-PSCSC Consortium; International IBD Genetics Consortium, Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, Färkkilä M, Dale AM, Chapman RW, Lazaridis KN; International PSC Study Group, Franke A, Anderson CA, Karlsen TH. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013;45(6): 670-675.

Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH, Nguyen TT, Maxwell AE, Bowlus CL, Bastani R, Nguyen TT. Increasing hepatitis B screening for Hmong adults: results from a randomized controlled community-based study. Cancer Epidemiology, Biomarkers & Prevention, 2013;22(5): 782-91.

Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB, Rothschild KJ, Bowlus CL, Adamopoulos IE, Leung PS, Janssen HJ, Cheung AC, Coltescu C, Gershwin ME. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2014.